Pancreatic Cancer Research

Clinical trialPhase 2Active not recruiting

Cisplatin and Etoposide Versus Temozolomide and Capecitabine in Patients With Advanced Poorly Differentiated (G3) Non-Small Cell Gastrointestinal Neuroendocrine Carcinomas

Randomized Phase II Study of Cisplatin and Etoposide Versus Temozolomide and Capecitabine in Patients With Advanced Poorly Differentiated (G3) Non-Small Cell Gastrointestinal Neuroendocrine Carcinomas

Outcome
Ongoing. Primary endpoint: no statistically significant difference (p = 0.3, as posted; no threshold posted, 0.05 used)
Phase
Phase 2
Status
Active not recruiting
Study type
Interventional
Start
6 November 2015
Expected end
1 January 2029
Enrollment
67 participants
Sites
673
Primary outcomes
Progression-free Survival (PFS)
Sponsor type
Network
Results posted
8 April 2026
Last update
2 November 2026

These fields come from the trial’s registry entry. A summary of its population, design, endpoints and results, each tied to a quote, has not been written for this trial yet.

Results

Primary endpoint
Primary endpoint: no statistically significant difference (p = 0.3, as posted; no threshold posted, 0.05 used)As posted on ClinicalTrials.gov ↗, registry record of 2 November 2026
PFS
Progression-free Survival (PFS)Arm A (Capecitabine, Temozolomide): 3.1 (2.1 to 8.4), n = 31Arm B (Cisplatin, Carboplatin, Etoposide): 5.5 (4.0 to 8.0), n = 32Arm A (Capecitabine, Temozolomide) vs Arm B (Cisplatin, Carboplatin, Etoposide): p = 0.3; Log Rank (not statistically significant against 0.05 (no threshold posted); outcome 1, analysis 1)Values: median months, 95% Confidence IntervalTime frame: assessed at baseline, every 8 weeks until treatment completion, then every 3 months within 2 years and every 6 months within 3-5 years from randomization until disease progression, up to 5 years from study registration
Participants
Arm A (Capecitabine, Temozolomide): 32 started, 0 completedArm B (Cisplatin, Carboplatin, Etoposide): 35 started, 0 completed
Serious adverse events
Arm A (Capecitabine, Temozolomide): 9 of 28Arm B (Cisplatin, Carboplatin, Etoposide): 20 of 29Participants with at least one serious adverse event, of those at risk, as posted
2 secondary outcomes
OS · Overall Survival (OS)
Arm A (Capecitabine, Temozolomide) 12.6 (5.4 to 30.3), n=31; Arm B (Cisplatin, Carboplatin, Etoposid… 10.8 (9.6 to 21.1), n=32 [median months, 95% Confidence Interval] Arm A (Capecitabine, Temozolomide) vs Arm B (Cisplatin, Carboplatin, Etoposid…: Cox Proportional Hazard 1.12 (95% CI 0.62 to 2.02); p = 0.35; Log Rank
ORR · Objective Response Rate (ORR)
Arm A (Capecitabine, Temozolomide) 19 (7 to 37), n=31; Arm B (Cisplatin, Carboplatin, Etoposid… 31 (16 to 50), n=32 [percentage of participants, 95% Confidence Interval] Arm A (Capecitabine, Temozolomide) vs Arm B (Cisplatin, Carboplatin, Etoposid…: Odds Ratio (OR) 0.53 (95% CI 0.14 to 1.94); p = 0.39; Regression, Logistic

Every value is copied from the trial’s results record at ClinicalTrials.gov. “Statistically significant” describes the posted test only: it does not say which group did better, and nothing here is read from a paper.

Ask this document

Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.

Try

Source text

Brief summary public domain (ClinicalTrials.gov)

This randomized phase II trial studies how well temozolomide and capecitabine work compared to standard treatment with cisplatin or carboplatin and etoposide in treating patients with neuroendocrine carcinoma of the gastrointestinal tract or pancreas that has spread to other parts of the body (metastatic) or cannot be removed by surgery. Drugs used in chemotherapy, such as temozolomide, capecitabine, cisplatin, carboplatin and etoposide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Certain types of neuroendocrine carcinomas may respond better to treatments other than the current standard treatment of cisplatin and etoposide. It is not yet known whether temozolomide and capecitabine may work better than cisplatin or carboplatin and etoposide in treating patients with this type of neuroendocrine carcinoma, called non-small cell neuroendocrine carcinoma.

Detailed description public domain (ClinicalTrials.gov)

PRIMARY OBJECTIVES: I. To assess the progression free survival (PFS) of platinum (cisplatin or carboplatin) and etoposide versus the PFS of temozolomide and capecitabine in patients with advanced G3 non-small cell gastroenteropancreatic neuroendocrine carcinomas. SECONDARY OBJECTIVES: I. To assess the response rate (RR) of platinum (cisplatin or carboplatin) and etoposide versus the RR of temozolomide and capecitabine in patients with advanced G3 non-small cell gastroenteropancreatic neuroendocrine carcinomas. II. To assess the overall survival (OS) of platinum (cisplatin or carboplatin) and etoposide versus the OS of temozolomide and capecitabine in patients with advanced G3 non-small cell gastroenteropancreatic neuroendocrine carcinomas. III. To evaluate the toxicities associated with the combination of temozolomide and capecitabine and the combination of platinum (cisplatin or carboplatin) and etoposide, respectively, in patients with advanced G3 non-small cell gastroenteropancreatic neuroendocrine carcinomas. TERTIARY OBJECTIVES: I. To assess the impact of each treatment regimen on PFS, RR and OS based on marker of proliferation Ki-67 index in patients with advanced G3 non-small cell gastroenteropancreatic neuroendocrine carcinomas. (Laboratory) II. To assess the prognostic significance of well differentiated versus poorly differentiated non-small cell gastroenteropancreatic neuroendocrine tumors in relationship to survival and response to treatment. (Laboratory) III. To assess the agreement in Ki-67 status between that reported by institutional pathologist and that reported by central pathology review. (Laboratory) OUTLINE: Patients are randomized to 1 of 2 treatment arms. ARM A: Patients receive capecitabine orally (PO) twice daily (BID) on days 1-14 and temozolomide PO once daily (QD) on days 10-14. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. ARM B: Patients receive cisplatin intravenously (IV) on days 1-3 or carboplatin IV on day 1. Patients also receive etoposide IV on days 1-3. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed up every 3 months for 2 years and then every 6 months for 3 years.

Posted results (ClinicalTrials.gov registry) · primary outcome public domain (ClinicalTrials.gov)

Progression-free Survival (PFS) [assessed at baseline, every 8 weeks until treatment completion, then every 3 months within 2 years and every 6 months within 3-5 years from randomization until disease progression, up to 5 years from study registration]. Median, months (95% Confidence Interval). Arm A (Capecitabine, Temozolomide) (n=31): 3.1 (2.1 to 8.4); Arm B (Cisplatin, Carboplatin, Etoposide) (n=32): 5.5 (4.0 to 8.0). Analysis, Arm A (Capecitabine, Temozolomide) vs Arm B (Cisplatin, Carboplatin, Etoposide): p=0.3; Log Rank; superiority.

Posted results (ClinicalTrials.gov registry) · secondary outcome public domain (ClinicalTrials.gov)

Overall Survival (OS) [assessed at baseline, then every 3 months within 2 years from randomization, and every 6 months if patient is 3-5 years from randomization, up to 5 years from randomization]. Median, months (95% Confidence Interval). Arm A (Capecitabine, Temozolomide) (n=31): 12.6 (5.4 to 30.3); Arm B (Cisplatin, Carboplatin, Etoposide) (n=32): 10.8 (9.6 to 21.1). Analysis, Arm A (Capecitabine, Temozolomide) vs Arm B (Cisplatin, Carboplatin, Etoposide): Cox Proportional Hazard 1.12 (95% CI 0.62 to 2.02); p=0.35; Log Rank; superiority.

Posted results (ClinicalTrials.gov registry) · secondary outcome public domain (ClinicalTrials.gov)

Objective Response Rate (ORR) [assessed at baseline, every 8 weeks until treatment completion, then every 3 months within 2 years and every 6 months within 3-5 years, up to 5 years from registration; the best response among all assessments was considered as objective response]. Number, percentage of participants (95% Confidence Interval). Arm A (Capecitabine, Temozolomide) (n=31): 19 (7 to 37); Arm B (Cisplatin, Carboplatin, Etoposide) (n=32): 31 (16 to 50). Analysis, Arm A (Capecitabine, Temozolomide) vs Arm B (Cisplatin, Carboplatin, Etoposide): Odds Ratio (OR) 0.53 (95% CI 0.14 to 1.94); p=0.39; Regression, Logistic; superiority.